Lifecore Biomedical Stock (NASDAQ:LFCR)


ForecastRevenueFinancialsChartTranscripts

Previous Close

$7.07

52W Range

$3.68 - $8.90

50D Avg

$6.46

200D Avg

$5.85

Market Cap

$266.63M

Avg Vol (3M)

$169.23K

Beta

0.94

Div Yield

-

LFCR Company Profile


Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. It operates through Lifecore, Curation Foods, and Other segments. The Lifecore segment engages in the manufacture of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, including technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. This segment sells its non-HA products for medical use primarily in the ophthalmic, orthopedic, and other markets. The Curation Foods segment engages in processing, marketing, and selling of olive oils and wine vinegars under the O brand; and guacamole and avocado food products under the Yucatan and Cabo Fresh brands, as well as various private labels. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was incorporated in 1986 and is headquartered in Santa Maria, California.

Show More

Industry

Drug Manufacturers - Specialty & Generic

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

524

IPO Date

Feb 15, 1996

Website

LFCR Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceMay 24
Product and Service, Other-

Fiscal year ends in May 24 | Currency in USD

LFCR Financial Summary


May 24May 23May 22
Revenue$128.26M$103.27M$185.79M
Operating Income$9.33M$-26.08M$3.46M
Net Income$12.01M$-102.19M$-46.08M
EBITDA$9.33M$-11.12M$21.25M
Basic EPS$0.39$-3.41$-1.56
Diluted EPS$0.33$-3.41$-1.56

Fiscal year ends in May 24 | Currency in USD

Latest Earnings Call Transcripts


Q1 25Oct 04, 24 | 10:59 AM
Q4 24Aug 27, 24 | 1:56 PM
Q4 23Aug 31, 23 | 2:40 PM

Peer Comparison


TickerCompany
TLRYTilray Brands, Inc.
SHPHShuttle Pharmaceuticals Holdings, Inc.
DERMJourney Medical Corporation
AKANAkanda Corp.
IRWDIronwood Pharmaceuticals, Inc.
CPIXCumberland Pharmaceuticals Inc.
KMDAKamada Ltd.
CTLTCatalent, Inc.